Zevra Therapeutics Inc. (ZVRA), a commercial-stage company developing treatments for rare diseases, has announced financial results for the fourth quarter and full year that ended Dec.31, 2024.
The company's marketed drugs include OLPRUVA for the treatment of Urea Cycle Disorders, recently approved MIPLYFFA for the treatment of Niemann Pick disease type C, and *AZSTARYS for the treatment of Attention Deficit and Hyperactivity Disorder. *AZSTARYS is a partnered program with Commave Therapeutics.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.